To mitigate the risk of graft-versus-host disease, the T-cell receptor alpha constant gene was deleted, and CD52 was ablated to enhance lymphodepletion using ALLO647 (a humanized anti-CD52 antibody) in combination with fludarabine and cyclophosphamide. Here, CD52 is linked to graft versus host disease.